Fangyan Zhong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Fangyan Zhong has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Jingao Li
NHC Key Laboratory of Personalized Diagnosis and Treatment of Nasopharyngeal Carcinoma, Jiangxi Cancer Hospital, The Second Affiliated Hospital of Nanchang Medical College, Nanchang, Jiangxi 330029, PR China; Department of Radiation Oncology, Jiangxi Clinical Research Center for Cancer, Jiangxi Cancer Hospital, Nanchang Jiangxi 330029, PR China
2 shared publications - Tianzhu Lu
NHC Key Laboratory of Personalized Diagnosis and Treatment of Nasopharyngeal Carcinoma, Jiangxi Cancer Hospital, Nanchang, Jiangxi, 330029, People’s Republic of China
2 shared publications Bi‐Juan Chen
Department of Radiation Oncology Fujian Medical University Cancer Hospital & Fujian Cancer Hospital Fuzhou China
1 shared publicationChao Chen
Department of Radiotherapy The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine) Hangzhou Zhejiang China
1 shared publicationFu‐Juan Zeng
NHC Key Laboratory of Personalized Diagnosis and Treatment of Nasopharyngeal Carcinoma Jiangxi Clinical Research Center for Cancer, Jiangxi Cancer Hospital, The Second Affiliated Hospital of Nanchang Medical College Nanchang Jiangxi China
1 shared publicationHao Zhang
Department of Radiation Oncology, Hubei Cancer Hospital, Tongji Medical College Huazhong University of Science and Technology Wuhan China
1 shared publication
Latest Publications
- 4 October 2026
- Published by Wiley in The Laryngoscope
Pretreatment Health‐Related Quality of Life and Survival in Head and Neck Cancer: A Meta‐Analysis
Objective: To quantify associations between pretreatment patient‐reported health‐related quality of life (HRQoL) domains and overall survival in head and neck cancer. Data Sources: PubMed, Embase, and Web of Science were searched from inception through July 27, 2026. Review Methods: Longitudinal studies evaluating validated patient‐reported HRQoL as a prognostic exposure were included. Adjusted hazard ratios (HRs) for overall survival were harmonized to a 10‐point worsening and pooled by domain using restricted maximum‐likelihood random‐effects models. Risk of bias, multiplicity, leave‐one‐out stability, cohort overlap, residual‐confounding sensitivity, and reporting completeness were evaluated. Results: Thirty‐two independent studies in 40 publications were included; 43 estimates contributed to meta‐analyses of 10 domains. Worse Global QoL (HR, 1.11; 95% CI, 1.08–1.14), physical functioning (1.16; 1.13–1.20), role functioning (1.09; 1.07–1.11), and social functioning (1.09; 1.06–1.12) were consistently associated with higher mortality and remained leave‐one‐out stable. Swallowing was associated with mortality (1.15; 1.02–1.29) but was sensitive to one study. Dyspnea was associated with higher mortality in the primary analysis (4 studies; HR, 1.16; 95% CI, 1.01–1.33), but the estimate was heterogeneous and unstable. Conclusion: Pretreatment HRQoL provides multidimensional prognostic information, with Global QoL and physical, role, emotional, and social functioning showing the most consistent evidence. These domains may help prioritize pretreatment supportive‐care assessment, whereas sensitivity‐limited or very‐low‐certainty findings require further confirmation and should not be interpreted as actionable treatment targets. Level of Evidence: N/A. Trial Registration: PROSPERO number: CRD420261461389.
- 4 October 2026
- Published by Wiley in The Laryngoscope
Pretreatment Health‐Related Quality of Life and Survival in Head and Neck Cancer: A Meta‐Analysis
Objective: To quantify associations between pretreatment patient‐reported health‐related quality of life (HRQoL) domains and overall survival in head and neck cancer. Data Sources: PubMed, Embase, and Web of Science were searched from inception through July 27, 2026. Review Methods: Longitudinal studies evaluating validated patient‐reported HRQoL as a prognostic exposure were included. Adjusted hazard ratios (HRs) for overall survival were harmonized to a 10‐point worsening and pooled by domain using restricted maximum‐likelihood random‐effects models. Risk of bias, multiplicity, leave‐one‐out stability, cohort overlap, residual‐confounding sensitivity, and reporting completeness were evaluated. Results: Thirty‐two independent studies in 40 publications were included; 43 estimates contributed to meta‐analyses of 10 domains. Worse Global QoL (HR, 1.11; 95% CI, 1.08–1.14), physical functioning (1.16; 1.13–1.20), role functioning (1.09; 1.07–1.11), and social functioning (1.09; 1.06–1.12) were consistently associated with higher mortality and remained leave‐one‐out stable. Swallowing was associated with mortality (1.15; 1.02–1.29) but was sensitive to one study. Dyspnea was associated with higher mortality in the primary analysis (4 studies; HR, 1.16; 95% CI, 1.01–1.33), but the estimate was heterogeneous and unstable. Conclusion: Pretreatment HRQoL provides multidimensional prognostic information, with Global QoL and physical, role, emotional, and social functioning showing the most consistent evidence. These domains may help prioritize pretreatment supportive‐care assessment, whereas sensitivity‐limited or very‐low‐certainty findings require further confirmation and should not be interpreted as actionable treatment targets. Level of Evidence: N/A. Trial Registration: PROSPERO number: CRD420261461389.
- Open Access
- 11 December 2023
- Published by Wiley in Cancer Medicine
- Vol. 12 (24) , 22091-22102
Anatomic prognostic factors and their potential roles in refining M1 classification for de novo metastatic nasopharyngeal carcinoma
Background and Purpose: To identify anatomic prognostic factors and their potential roles in refining M1 classification for de novo metastatic nasopharyngeal carcinoma (M1‐NPC).Materials and Methods: All M1‐NPC treated with chemotherapy and/or radiotherapy between 2010 and 2019 from two centers (training and validation cohort) were included. The prognostic value of metastatic disease extent and involved organs for overall survival (OS) were assessed by several multivariable analyses (MVA) models. A new M1 classification was proposed and validated in a separate cohort who received immuno‐chemotherapy.Results: A total of 197 M1‐NPC in the training and 307 in the validation cohorts were included for M1 subdivision study with median follow‐up of 46 and 57 months. MVA model with “≤2 organs/≤5 lesions” as the definition of oligometastasis had the highest C‐index (0.623) versus others (0.606–0.621). Patients with oligometastasis had better OS versus polymetastasis (hazard ratio [HR] 0.47/0.63) while liver metastases carried worse OS (HR 1.57/1.45) in MVA in the training/validation cohorts, respectively. We proposed to divide M1‐NPC into M1a (oligometastasis without liver metastases) and M1b (liver metastases or polymetastasis) with 3‐year OS of 66.5%/31.7% and 64.9%/35.0% in the training/validation cohorts, respectively. M1a subset had a better median progress‐free survival (not reach vs. 17 months, p < 0.001) in the immuno‐chemotherapy cohort (n = 163).Conclusion: Oligometastasis (≤2 organs/≤5 lesions) and liver metastasis are prognostic for M1‐NPC. Subdivision of M1‐NPC into M1a (oligometastasis without liver metastasis) and M1b (liver metastasis or polymetastasis) depicts the prognosis well in M1‐NPC patients who received immuno‐chemotherapy.
- 11 December 2023
- Published by Wiley in Cancer Medicine
- Vol. 12 (24) , 22091-22102
Open AccessAnatomic prognostic factors and their potential roles in refining M1 classification for de novo metastatic nasopharyngeal carcinoma
Background and Purpose: To identify anatomic prognostic factors and their potential roles in refining M1 classification for de novo metastatic nasopharyngeal carcinoma (M1‐NPC).Materials and Methods: All M1‐NPC treated with chemotherapy and/or radiotherapy between 2010 and 2019 from two centers (training and validation cohort) were included. The prognostic value of metastatic disease extent and involved organs for overall survival (OS) were assessed by several multivariable analyses (MVA) models. A new M1 classification was proposed and validated in a separate cohort who received immuno‐chemotherapy.Results: A total of 197 M1‐NPC in the training and 307 in the validation cohorts were included for M1 subdivision study with median follow‐up of 46 and 57 months. MVA model with “≤2 organs/≤5 lesions” as the definition of oligometastasis had the highest C‐index (0.623) versus others (0.606–0.621). Patients with oligometastasis had better OS versus polymetastasis (hazard ratio [HR] 0.47/0.63) while liver metastases carried worse OS (HR 1.57/1.45) in MVA in the training/validation cohorts, respectively. We proposed to divide M1‐NPC into M1a (oligometastasis without liver metastases) and M1b (liver metastases or polymetastasis) with 3‐year OS of 66.5%/31.7% and 64.9%/35.0% in the training/validation cohorts, respectively. M1a subset had a better median progress‐free survival (not reach vs. 17 months, p < 0.001) in the immuno‐chemotherapy cohort (n = 163).Conclusion: Oligometastasis (≤2 organs/≤5 lesions) and liver metastasis are prognostic for M1‐NPC. Subdivision of M1‐NPC into M1a (oligometastasis without liver metastasis) and M1b (liver metastasis or polymetastasis) depicts the prognosis well in M1‐NPC patients who received immuno‐chemotherapy.
- Open Access
- 3 February 2022
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 13, 809872
A Signature of N6-methyladenosine Regulator-Related Genes Predicts Prognoses and Immune Responses for Head and Neck Squamous Cell Carcinoma
This study aimed to construct a signature of N6-methyladenosine (m6A) regulator-related genes that could be used for the prognosis of head and neck squamous cell carcinoma (HNSCC) and to clarify the molecular and immune characteristics and benefits of immune checkpoint inhibitor (ICI) therapy using the prognostic signature to define the subgroups of HNSCC. This study showed that eighteen m6A regulators were abnormally expressed in the Cancer Genome Atlas (TCGA) HNSCC tissues compared with those in normal tissues. We constructed a signature of 12 m6A regulator-related genes using the Cox risk model, combined with the least absolute shrinkage and selection operator (Lasso) variable screening algorithm. Based on the median of the signature risk score, the patients were divided into high- and low-risk groups. The Kaplan–Meier survival analyses showed that patients with high-risk scores demonstrated poorer overall survival (OS) than those with low-risk scores based on TCGA-HNSCC data (p <0.001). The OS of high-risk patients was significantly worse than that of low-risk patients in the GSE65858 (p <0.001) and International Cancer Genome Consortium (ICGC) oral cancer cohorts (p = 0.0089). Furthermore, immune infiltration analyses showed that 8 types of immune cell infiltration showed highly significant differences between the two risk groups (p <0.001). In the Imvigor210CoreBiologies dataset of patients who received ICIs, the objective response rate (ORR) of the low-risk group (32%) was significantly higher than that of the high-risk group (13%). Additionally, patients in the high-risk group presented with a more significant adverse OS than that of the low-risk group (p = 0.00032). GSE78220 also showed that the ORR of the low-risk group (64%) was higher than that of the high-risk group (43%) and the OS of low-risk patients was better than that of high-risk patients (p = 0.0064). The constructed prognostic signature, based on m6A regulator-related genes, could be used to effectively distinguish between prognoses for HNSCC patients. The prognostic signature was found to be related to the immune cell infiltration of HNSCC; it might help predict the responses and prognoses of ICIs during treatment.
- 3 February 2022
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 13, 809872
Open AccessA Signature of N6-methyladenosine Regulator-Related Genes Predicts Prognoses and Immune Responses for Head and Neck Squamous Cell Carcinoma
This study aimed to construct a signature of N6-methyladenosine (m6A) regulator-related genes that could be used for the prognosis of head and neck squamous cell carcinoma (HNSCC) and to clarify the molecular and immune characteristics and benefits of immune checkpoint inhibitor (ICI) therapy using the prognostic signature to define the subgroups of HNSCC. This study showed that eighteen m6A regulators were abnormally expressed in the Cancer Genome Atlas (TCGA) HNSCC tissues compared with those in normal tissues. We constructed a signature of 12 m6A regulator-related genes using the Cox risk model, combined with the least absolute shrinkage and selection operator (Lasso) variable screening algorithm. Based on the median of the signature risk score, the patients were divided into high- and low-risk groups. The Kaplan–Meier survival analyses showed that patients with high-risk scores demonstrated poorer overall survival (OS) than those with low-risk scores based on TCGA-HNSCC data (p <0.001). The OS of high-risk patients was significantly worse than that of low-risk patients in the GSE65858 (p <0.001) and International Cancer Genome Consortium (ICGC) oral cancer cohorts (p = 0.0089). Furthermore, immune infiltration analyses showed that 8 types of immune cell infiltration showed highly significant differences between the two risk groups (p <0.001). In the Imvigor210CoreBiologies dataset of patients who received ICIs, the objective response rate (ORR) of the low-risk group (32%) was significantly higher than that of the high-risk group (13%). Additionally, patients in the high-risk group presented with a more significant adverse OS than that of the low-risk group (p = 0.00032). GSE78220 also showed that the ORR of the low-risk group (64%) was higher than that of the high-risk group (43%) and the OS of low-risk patients was better than that of high-risk patients (p = 0.0064). The constructed prognostic signature, based on m6A regulator-related genes, could be used to effectively distinguish between prognoses for HNSCC patients. The prognostic signature was found to be related to the immune cell infiltration of HNSCC; it might help predict the responses and prognoses of ICIs during treatment.
- Open Access
- 21 May 2021
- Published by Wolters Kluwer Health in Medicine
- Vol. 100 (20) , e26000
Prone position versus supine position in postoperative radiotherapy for breast cancer
Background: This meta-analysis evaluates the difference of sparing organs at risk (OAR) in different position (Prone position and Supine position) with different breathing patterns (Free breathing, FB/Deep inspiration breath hold, DIBH) for breast cancer patients receiving postoperative radiotherapy and provides a useful reference for clinical practice. Method: The relevant controlled trials of prone position versus supine position in postoperative radiotherapy for breast cancer were retrieved from the sources of PubMed, Cochrane Library, Embase, Web of Science and ClinicalTrails.gov. The principal outcome of interest was OAR doses (heart dose, left anterior descending coronary artery dose and ipsilateral lung dose) and target coverage. We mainly compared the effects of P-FB (Prone position FB) and S-FB (Supine position FB) and discussed the effects of DIBH combined with different positions on OAR dose in postoperative radiotherapy. We calculated summary standardized mean difference (SMD) and 95% confidence intervals (CI). The meta-analysis was performed using RevMan 5.4 software. Results: The analysis included 751 patients from 19 observational studies. Compared with the S-FB, the P-FB can have lower heart dose, left anterior descending coronary artery (LADCA) dose, and ipsilateral lung dose (ILL) more effectively, and the difference was statistically significant (heart dose, SMD = − 0.51, 95% CI − 0.66 ∼ − 0.36, P < .00001. LADCA dose, SMD = − 0.58, 95% CI – 0.85 ∼ − 0.31, P < .0001. ILL dose, SMD = − 2.84, 95% CI − 3.2 ∼ − 2.48, P < .00001). And there was no significant difference in target coverage between the S-FB and P-FB groups (SMD = − 0.1, 95% CI − 0.57 ∼ 0.36, P = .66). Moreover, through descriptive analysis, we found that P-DIBH (Prone position DIBH) has better sparing OAR than P-FB and S-DIBH (Supine position DIBH). Conclusion: By this meta-analysis, compared with the S-FB we found that implementation of P-FB in postoperative radiotherapy for breast cancer can reduce irradiation of heart dose, LADCA dose and ILL dose, without compromising mean dose of target coverage. Moreover, P-DIBH might become the most promising way for breast cancer patients to undergo radiotherapy.
- 21 May 2021
- Published by Wolters Kluwer Health in Medicine
- Vol. 100 (20) , e26000
Open AccessProne position versus supine position in postoperative radiotherapy for breast cancer
Background: This meta-analysis evaluates the difference of sparing organs at risk (OAR) in different position (Prone position and Supine position) with different breathing patterns (Free breathing, FB/Deep inspiration breath hold, DIBH) for breast cancer patients receiving postoperative radiotherapy and provides a useful reference for clinical practice. Method: The relevant controlled trials of prone position versus supine position in postoperative radiotherapy for breast cancer were retrieved from the sources of PubMed, Cochrane Library, Embase, Web of Science and ClinicalTrails.gov. The principal outcome of interest was OAR doses (heart dose, left anterior descending coronary artery dose and ipsilateral lung dose) and target coverage. We mainly compared the effects of P-FB (Prone position FB) and S-FB (Supine position FB) and discussed the effects of DIBH combined with different positions on OAR dose in postoperative radiotherapy. We calculated summary standardized mean difference (SMD) and 95% confidence intervals (CI). The meta-analysis was performed using RevMan 5.4 software. Results: The analysis included 751 patients from 19 observational studies. Compared with the S-FB, the P-FB can have lower heart dose, left anterior descending coronary artery (LADCA) dose, and ipsilateral lung dose (ILL) more effectively, and the difference was statistically significant (heart dose, SMD = − 0.51, 95% CI − 0.66 ∼ − 0.36, P < .00001. LADCA dose, SMD = − 0.58, 95% CI – 0.85 ∼ − 0.31, P < .0001. ILL dose, SMD = − 2.84, 95% CI − 3.2 ∼ − 2.48, P < .00001). And there was no significant difference in target coverage between the S-FB and P-FB groups (SMD = − 0.1, 95% CI − 0.57 ∼ 0.36, P = .66). Moreover, through descriptive analysis, we found that P-DIBH (Prone position DIBH) has better sparing OAR than P-FB and S-DIBH (Supine position DIBH). Conclusion: By this meta-analysis, compared with the S-FB we found that implementation of P-FB in postoperative radiotherapy for breast cancer can reduce irradiation of heart dose, LADCA dose and ILL dose, without compromising mean dose of target coverage. Moreover, P-DIBH might become the most promising way for breast cancer patients to undergo radiotherapy.